Overall Survival With ctDNA-Guided Therapy in Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Nat. Med. 2022 Nov 01;28(11)2353-2363, J Jee, ES Lebow, R Yeh, JP Das, A Namakydoust, PK Paik, JE Chaft, G Jayakumaran, A Rose Brannon, R Benayed, A Zehir, M Donoghue, N Schultz, D Chakravarty, R Kundra, R Madupuri, YR Murciano-Goroff, HY Tu, CR Xu, A Martinez, C Wilhelm, J Galle, B Daly, HA Yu, M Offin, MD Hellmann, P Lito, KC Arbour, MG Zauderer, MG Kris, KK Ng, J Eng, I Preeshagul, W Victoria Lai, JJ Fiore, A Iqbal, D Molena, G Rocco, BJ Park, LP Lim, M Li, C Tong-Li, M De Silva, DL Chan, CI Diakos, M Itchins, S Clarke, N Pavlakis, A Lee, N Rekhtman, J Chang, WD Travis, GJ Riely, DB Solit, M Gonen, VW Rusch, A Rimner, D Gomez, A Drilon, HI Scher, SP Shah, MF Berger, ME Arcila, M Ladanyi, RL Levine, R Shen, P Razavi, JS Reis-Filho, DR Jones, CM Rudin, JM Isbell, BT LiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.